Mayaro virus (MAYV) was discovered in the blood of forest laborers in Trinidad in 1954. MAYV, like similar alphaviruses, can infect, multiply, and spread in vertebrate & invertebrate species. The virus causes Mayaro fever in humans and is characterized by long-lasting arthralgia like Dengue fever. Although mortality among infected individuals is now rare, Mayaro fever could develop into an essential concern for the public, particularly in rural regions, as the Amazon region’s prevalence rises due to environmental changes.
Mosquitoes are accountable for the propagation of several lethal infections, including MAYV, affecting the livelihoods and lives of millions of individuals worldwide each year. The global spread of the two urban severe carriers (Aedes aegypti & Aedes albopictus) and the growing number of foreign travelers will almost certainly raise the danger of MAYV transmission.
Mayaro virus has been reported as being prevalent in French Guiana since 1997; the frequency of RT-PCR findings of MAYV, according to IPG, between 2017 and 2019, respectively, comprised between 1-3 confirmed instances every year, discovered in samples ranging from 150 to nearly 600.
MAYV vectors (Haemagogus species mosquitoes) are also vectors of the sylvatic phase of the yellow fever virus. They are found in wild or rural environments throughout the Americas & the Caribbean. MAYV has been isolated from mosquitos of many species, including Culex, Mansonia, Psorophora, Aedes, & Sabethes.
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Alsuviricetes
Order: Martellivirales
Family: Togaviridae
Genus:Alphavirus
Species:Mayaro virus
The viral particles are approximately 11.5 kilobases (kb) long and contain a single-stranded RNA genome with 11,430 nucleotides and positive polarity.
The genome is organized into two open reading frames, encoding structural proteins and non-structural proteins. The non-structural polyprotein is cleaved into four individual proteins (nsP1, nsP2, nsP3, & nsP4) during and after translation, while the structural genes produce six structural proteins (C, E1, E2, E3, 6K, & transframe).
The envelope of MAYV is formed by the host cell membrane, which is sealed with the E1-E2 complex. This compact envelope surrounds the nucleocapsid, creating the overall icosahedral structure of the virus.
Currently, three antigenic types of MAYV have been identified: L, N, and D. The L type is considered the prototype strain. It is the most common type reported in South and Central America, representing the original isolate of MAYV. On the other hand, the N (1999, Nigeria) and D types (2006, French Guiana) are distinct genetic lineages or subtypes within the MAYV species. These types have unique genetic characteristics and exhibit different antigenic properties, leading to differences in their reactivity with specific antibodies in serological assays.
The E2 glycoprotein of the Mayaro virus (MAYV) contains specific antigenic epitopes that antibodies can recognize. One such epitope is p_MAYV4 and is in domain A of the E2 glycoprotein. This specific epitope has been identified as a target for antibody binding and immune recognition.
After a bite from an infected vector, such as mosquitoes of the Haemagogus and Aedes species, the Mayaro virus (MAYV) enters the body. It spreads via the bloodstream to various tissues and organs. The virus primarily targets white blood cells, specifically monocytes and macrophages, where it undergoes replication. From there, the virus can disseminate to other body parts, including bones, muscles, and joints.
Studies have demonstrated that MAYV can infect and replicate within primary human chondrocytes, which are responsible for maintaining the structure and function of cartilage in joints. The infection of chondrocytes can lead to the dysregulation of various genes associated with joint inflammation and tissue remodeling, potentially contributing to the development of arthralgia.
Similarly, osteoblasts, which are involved in bone formation, and synoviocytes, the cells lining the synovial membrane of joints, have also been shown to be permissive to MAYV infection. Infection of these cells can result in the upregulation of inflammation-related genes, immune response, and extracellular matrix remodeling, which are implicated in joint pathology.
During MAYV infection, macrophages can become infected and serve as viral reservoirs. Infected macrophages produce pro-inflammatory molecules, such as tumor necrosis factor alpha. TNF-α promotes the recruitment of immune cells and amplifies the inflammatory response, contributing to the development of arthritis. Additionally, macrophages generate excessive reactive oxygen species, leading to oxidative stress and tissue damage, including joint damage.
Innate immune response:
Infection of bone marrow-derived macrophages with the Mayaro virus (MAYV) leads to the upregulation (overexpression) of essential inflammasome proteins. In particular, the NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) and AIM2 (absent in melanoma 2) inflammasomes have been implicated in response to MAYV infection. Activation of these inflammasomes triggers the assembly of the inflammasome complex, including the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and subsequently activates caspase enzymes.
The activation of caspases, particularly caspase-1, leads to the synthesis and release of pro-inflammatory cytokines, like interleukin-1β (IL-1β) and interleukin-18 (IL-18), essential mediators of the inflammatory response. The upregulation of NLRP3, AIM2, ASC, and caspase proteins in infected macrophages indicates the involvement of the inflammasome pathway in the host immune response to MAYV infection.
Antibody response:
MAYV stimulates the production of immunoglobulin M (IgM) antibodies during acute infection. IgM antibodies are the first to produce in response to an infection and indicate a recent or active immune response. MAYV-specific IgM antibodies typically last for at least three months after the onset of clinical symptoms, serving as an indicator of recent infection.
On the other hand, the presence of immunoglobulin G (IgG) antibodies indicates prior exposure or infection with MAYV. IgG antibodies are produced later during the immune response and persist for longer, even after the infection has resolved.
Mayaro virus (MAYV) infection in humans can lead to various clinical manifestations like other arboviral diseases.
Fever:Mayaro virus infection typically presents with a sudden onset of high fever, often exceeding 39°C (104°F).
Joint and muscle pain: Severe joint pain (arthralgia) is a hallmark of the Mayaro virus infection. It commonly affects the large joints such as the knees, ankles, and wrists. Muscle pain (myalgia) and stiffness are also frequently reported.
Rash: Many individuals infected with the Mayaro virus develop a rash, which can vary in appearance and distribution. The rash is often maculopapular (flat or slightly raised) and may affect the trunk, limbs, and face.
Headache: Headache, including retro-orbital pain (pain behind the eyes), is commonly reported in Mayaro virus infection.
Fatigue: Profound fatigue and weakness are common symptoms during the acute phase of the Mayaro virus infection.
Other symptoms: Additional symptoms that may be observed include nausea, vomiting, diarrhea, sore throat, conjunctivitis (inflammation of the conjunctiva), and respiratory symptoms like coughing.
ELISA: It detects and quantifies specific antibodies (IgM and IgG) produced in response to MAYV infection. The test relies on antigen-antibody binding, where MAYV-specific antigens are immobilized on a solid surface, and the patient’s serum is added. If the patient has been infected with MAYV, the specific antibodies will bind to the antigens. The presence and number of MAYV-specific antibodies can be measured using enzyme-labeled secondary antibodies and a colorimetric substrate.
Complement fixation: Antibody affinity to the E2 protein of the Mayaro virus (MAYV) refers to the strength of binding between antibodies and the E2 protein, a viral envelope protein. Antibodies with higher affinity exhibit stronger binding interactions with the E2 protein. Binding to the E2 protein is essential for the immune response against MAYV, as antibodies that bind to E2 can neutralize the virus by preventing its attachment to host cells and interfering with viral replication. The neutralization of anti-MAYV monoclonal antibodies (mAbs) occurs when these antibodies bind to E2, inhibiting viral infectivity. The complement fixing experiment is an immunological technique to identify antibodies against MAYV. Blending patient serum with MAYV antigens & complement proteins resulted in complement activation & concurrent lysis of indicator cells, demonstrating the existence of specific antibodies against the Mayaro virus.
Neutralization tests: These tests assess the ability of patient serum to neutralize the infectivity of MAYV in cell culture. In a neutralization test, patient serum samples are diluted and mixed with a standardized amount of live MAYV. The serum-virus mixture is then added to susceptible cells and incubated. If the patient’s serum contains specific antibodies against MAYV, these antibodies will bind to the virus, preventing it from infecting the cells. The neutralization effect is measured by assessing the cell level of viral replication or cytopathic effect. A decrease or absence of viral replication indicates the presence of neutralizing antibodies and confirms the diagnosis of MAYV infection. Neutralization tests provide a specific and sensitive means of detecting antibodies against MAYV and are particularly useful in determining past or recent exposure to the virus.
When diagnosing Mayaro virus infection, it is crucial to consider possible cross-reactions; the Alphavirus genus shares similar antigenic properties, leading to potential cross-reactivity in serological tests. Cross-reactivity means that antibodies produced in response to one virus may also recognize and bind to antigens of another virus. Accurate diagnosis of MAYV requires using specific antigens and careful interpretation of serological test results to differentiate between MAYV-specific antibodies and those generated against chikungunya virus or O’nyong-nyongvirus.
RT-PCR test: The design of a reverse transcription real-time PCR (rRT-PCR) targeting a region of the 5′ untranslated region (UTR) and nsp1 gene of Mayaro virus allows for accurate detection of the virus. The 5′ UTR region is conserved in the viral genome, while the nsp1 gene encodes a non-structural protein. The rRT-PCR assay can detect and amplify the Mayaro virus genetic material in clinical samples by targeting these specific regions.
Vector control: Since MAYV is primarily transmitted by mosquitoes, controlling mosquito populations is crucial. It can be achieved by eliminating breeding sites, using insecticide-treated bed nets, applying insect repellents, and implementing community-based mosquito control programs.
Individuals living in or visiting areas where MAYV is endemic should take personal protective measures, including wearing long-sleeved clothing, using insect repellents, and staying in screened or air-conditioned accommodations to minimize mosquito bites.
Mayaro virus (MAYV) was discovered in the blood of forest laborers in Trinidad in 1954. MAYV, like similar alphaviruses, can infect, multiply, and spread in vertebrate & invertebrate species. The virus causes Mayaro fever in humans and is characterized by long-lasting arthralgia like Dengue fever. Although mortality among infected individuals is now rare, Mayaro fever could develop into an essential concern for the public, particularly in rural regions, as the Amazon region’s prevalence rises due to environmental changes.
Mosquitoes are accountable for the propagation of several lethal infections, including MAYV, affecting the livelihoods and lives of millions of individuals worldwide each year. The global spread of the two urban severe carriers (Aedes aegypti & Aedes albopictus) and the growing number of foreign travelers will almost certainly raise the danger of MAYV transmission.
Mayaro virus has been reported as being prevalent in French Guiana since 1997; the frequency of RT-PCR findings of MAYV, according to IPG, between 2017 and 2019, respectively, comprised between 1-3 confirmed instances every year, discovered in samples ranging from 150 to nearly 600.
MAYV vectors (Haemagogus species mosquitoes) are also vectors of the sylvatic phase of the yellow fever virus. They are found in wild or rural environments throughout the Americas & the Caribbean. MAYV has been isolated from mosquitos of many species, including Culex, Mansonia, Psorophora, Aedes, & Sabethes.
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Alsuviricetes
Order: Martellivirales
Family: Togaviridae
Genus:Alphavirus
Species:Mayaro virus
The viral particles are approximately 11.5 kilobases (kb) long and contain a single-stranded RNA genome with 11,430 nucleotides and positive polarity.
The genome is organized into two open reading frames, encoding structural proteins and non-structural proteins. The non-structural polyprotein is cleaved into four individual proteins (nsP1, nsP2, nsP3, & nsP4) during and after translation, while the structural genes produce six structural proteins (C, E1, E2, E3, 6K, & transframe).
The envelope of MAYV is formed by the host cell membrane, which is sealed with the E1-E2 complex. This compact envelope surrounds the nucleocapsid, creating the overall icosahedral structure of the virus.
Currently, three antigenic types of MAYV have been identified: L, N, and D. The L type is considered the prototype strain. It is the most common type reported in South and Central America, representing the original isolate of MAYV. On the other hand, the N (1999, Nigeria) and D types (2006, French Guiana) are distinct genetic lineages or subtypes within the MAYV species. These types have unique genetic characteristics and exhibit different antigenic properties, leading to differences in their reactivity with specific antibodies in serological assays.
The E2 glycoprotein of the Mayaro virus (MAYV) contains specific antigenic epitopes that antibodies can recognize. One such epitope is p_MAYV4 and is in domain A of the E2 glycoprotein. This specific epitope has been identified as a target for antibody binding and immune recognition.
After a bite from an infected vector, such as mosquitoes of the Haemagogus and Aedes species, the Mayaro virus (MAYV) enters the body. It spreads via the bloodstream to various tissues and organs. The virus primarily targets white blood cells, specifically monocytes and macrophages, where it undergoes replication. From there, the virus can disseminate to other body parts, including bones, muscles, and joints.
Studies have demonstrated that MAYV can infect and replicate within primary human chondrocytes, which are responsible for maintaining the structure and function of cartilage in joints. The infection of chondrocytes can lead to the dysregulation of various genes associated with joint inflammation and tissue remodeling, potentially contributing to the development of arthralgia.
Similarly, osteoblasts, which are involved in bone formation, and synoviocytes, the cells lining the synovial membrane of joints, have also been shown to be permissive to MAYV infection. Infection of these cells can result in the upregulation of inflammation-related genes, immune response, and extracellular matrix remodeling, which are implicated in joint pathology.
During MAYV infection, macrophages can become infected and serve as viral reservoirs. Infected macrophages produce pro-inflammatory molecules, such as tumor necrosis factor alpha. TNF-α promotes the recruitment of immune cells and amplifies the inflammatory response, contributing to the development of arthritis. Additionally, macrophages generate excessive reactive oxygen species, leading to oxidative stress and tissue damage, including joint damage.
Innate immune response:
Infection of bone marrow-derived macrophages with the Mayaro virus (MAYV) leads to the upregulation (overexpression) of essential inflammasome proteins. In particular, the NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) and AIM2 (absent in melanoma 2) inflammasomes have been implicated in response to MAYV infection. Activation of these inflammasomes triggers the assembly of the inflammasome complex, including the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and subsequently activates caspase enzymes.
The activation of caspases, particularly caspase-1, leads to the synthesis and release of pro-inflammatory cytokines, like interleukin-1β (IL-1β) and interleukin-18 (IL-18), essential mediators of the inflammatory response. The upregulation of NLRP3, AIM2, ASC, and caspase proteins in infected macrophages indicates the involvement of the inflammasome pathway in the host immune response to MAYV infection.
Antibody response:
MAYV stimulates the production of immunoglobulin M (IgM) antibodies during acute infection. IgM antibodies are the first to produce in response to an infection and indicate a recent or active immune response. MAYV-specific IgM antibodies typically last for at least three months after the onset of clinical symptoms, serving as an indicator of recent infection.
On the other hand, the presence of immunoglobulin G (IgG) antibodies indicates prior exposure or infection with MAYV. IgG antibodies are produced later during the immune response and persist for longer, even after the infection has resolved.
Mayaro virus (MAYV) infection in humans can lead to various clinical manifestations like other arboviral diseases.
Fever:Mayaro virus infection typically presents with a sudden onset of high fever, often exceeding 39°C (104°F).
Joint and muscle pain: Severe joint pain (arthralgia) is a hallmark of the Mayaro virus infection. It commonly affects the large joints such as the knees, ankles, and wrists. Muscle pain (myalgia) and stiffness are also frequently reported.
Rash: Many individuals infected with the Mayaro virus develop a rash, which can vary in appearance and distribution. The rash is often maculopapular (flat or slightly raised) and may affect the trunk, limbs, and face.
Headache: Headache, including retro-orbital pain (pain behind the eyes), is commonly reported in Mayaro virus infection.
Fatigue: Profound fatigue and weakness are common symptoms during the acute phase of the Mayaro virus infection.
Other symptoms: Additional symptoms that may be observed include nausea, vomiting, diarrhea, sore throat, conjunctivitis (inflammation of the conjunctiva), and respiratory symptoms like coughing.
ELISA: It detects and quantifies specific antibodies (IgM and IgG) produced in response to MAYV infection. The test relies on antigen-antibody binding, where MAYV-specific antigens are immobilized on a solid surface, and the patient’s serum is added. If the patient has been infected with MAYV, the specific antibodies will bind to the antigens. The presence and number of MAYV-specific antibodies can be measured using enzyme-labeled secondary antibodies and a colorimetric substrate.
Complement fixation: Antibody affinity to the E2 protein of the Mayaro virus (MAYV) refers to the strength of binding between antibodies and the E2 protein, a viral envelope protein. Antibodies with higher affinity exhibit stronger binding interactions with the E2 protein. Binding to the E2 protein is essential for the immune response against MAYV, as antibodies that bind to E2 can neutralize the virus by preventing its attachment to host cells and interfering with viral replication. The neutralization of anti-MAYV monoclonal antibodies (mAbs) occurs when these antibodies bind to E2, inhibiting viral infectivity. The complement fixing experiment is an immunological technique to identify antibodies against MAYV. Blending patient serum with MAYV antigens & complement proteins resulted in complement activation & concurrent lysis of indicator cells, demonstrating the existence of specific antibodies against the Mayaro virus.
Neutralization tests: These tests assess the ability of patient serum to neutralize the infectivity of MAYV in cell culture. In a neutralization test, patient serum samples are diluted and mixed with a standardized amount of live MAYV. The serum-virus mixture is then added to susceptible cells and incubated. If the patient’s serum contains specific antibodies against MAYV, these antibodies will bind to the virus, preventing it from infecting the cells. The neutralization effect is measured by assessing the cell level of viral replication or cytopathic effect. A decrease or absence of viral replication indicates the presence of neutralizing antibodies and confirms the diagnosis of MAYV infection. Neutralization tests provide a specific and sensitive means of detecting antibodies against MAYV and are particularly useful in determining past or recent exposure to the virus.
When diagnosing Mayaro virus infection, it is crucial to consider possible cross-reactions; the Alphavirus genus shares similar antigenic properties, leading to potential cross-reactivity in serological tests. Cross-reactivity means that antibodies produced in response to one virus may also recognize and bind to antigens of another virus. Accurate diagnosis of MAYV requires using specific antigens and careful interpretation of serological test results to differentiate between MAYV-specific antibodies and those generated against chikungunya virus or O’nyong-nyongvirus.
RT-PCR test: The design of a reverse transcription real-time PCR (rRT-PCR) targeting a region of the 5′ untranslated region (UTR) and nsp1 gene of Mayaro virus allows for accurate detection of the virus. The 5′ UTR region is conserved in the viral genome, while the nsp1 gene encodes a non-structural protein. The rRT-PCR assay can detect and amplify the Mayaro virus genetic material in clinical samples by targeting these specific regions.
Vector control: Since MAYV is primarily transmitted by mosquitoes, controlling mosquito populations is crucial. It can be achieved by eliminating breeding sites, using insecticide-treated bed nets, applying insect repellents, and implementing community-based mosquito control programs.
Individuals living in or visiting areas where MAYV is endemic should take personal protective measures, including wearing long-sleeved clothing, using insect repellents, and staying in screened or air-conditioned accommodations to minimize mosquito bites.
Mayaro virus (MAYV) was discovered in the blood of forest laborers in Trinidad in 1954. MAYV, like similar alphaviruses, can infect, multiply, and spread in vertebrate & invertebrate species. The virus causes Mayaro fever in humans and is characterized by long-lasting arthralgia like Dengue fever. Although mortality among infected individuals is now rare, Mayaro fever could develop into an essential concern for the public, particularly in rural regions, as the Amazon region’s prevalence rises due to environmental changes.
Mosquitoes are accountable for the propagation of several lethal infections, including MAYV, affecting the livelihoods and lives of millions of individuals worldwide each year. The global spread of the two urban severe carriers (Aedes aegypti & Aedes albopictus) and the growing number of foreign travelers will almost certainly raise the danger of MAYV transmission.
Mayaro virus has been reported as being prevalent in French Guiana since 1997; the frequency of RT-PCR findings of MAYV, according to IPG, between 2017 and 2019, respectively, comprised between 1-3 confirmed instances every year, discovered in samples ranging from 150 to nearly 600.
MAYV vectors (Haemagogus species mosquitoes) are also vectors of the sylvatic phase of the yellow fever virus. They are found in wild or rural environments throughout the Americas & the Caribbean. MAYV has been isolated from mosquitos of many species, including Culex, Mansonia, Psorophora, Aedes, & Sabethes.
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Alsuviricetes
Order: Martellivirales
Family: Togaviridae
Genus:Alphavirus
Species:Mayaro virus
The viral particles are approximately 11.5 kilobases (kb) long and contain a single-stranded RNA genome with 11,430 nucleotides and positive polarity.
The genome is organized into two open reading frames, encoding structural proteins and non-structural proteins. The non-structural polyprotein is cleaved into four individual proteins (nsP1, nsP2, nsP3, & nsP4) during and after translation, while the structural genes produce six structural proteins (C, E1, E2, E3, 6K, & transframe).
The envelope of MAYV is formed by the host cell membrane, which is sealed with the E1-E2 complex. This compact envelope surrounds the nucleocapsid, creating the overall icosahedral structure of the virus.
Currently, three antigenic types of MAYV have been identified: L, N, and D. The L type is considered the prototype strain. It is the most common type reported in South and Central America, representing the original isolate of MAYV. On the other hand, the N (1999, Nigeria) and D types (2006, French Guiana) are distinct genetic lineages or subtypes within the MAYV species. These types have unique genetic characteristics and exhibit different antigenic properties, leading to differences in their reactivity with specific antibodies in serological assays.
The E2 glycoprotein of the Mayaro virus (MAYV) contains specific antigenic epitopes that antibodies can recognize. One such epitope is p_MAYV4 and is in domain A of the E2 glycoprotein. This specific epitope has been identified as a target for antibody binding and immune recognition.
After a bite from an infected vector, such as mosquitoes of the Haemagogus and Aedes species, the Mayaro virus (MAYV) enters the body. It spreads via the bloodstream to various tissues and organs. The virus primarily targets white blood cells, specifically monocytes and macrophages, where it undergoes replication. From there, the virus can disseminate to other body parts, including bones, muscles, and joints.
Studies have demonstrated that MAYV can infect and replicate within primary human chondrocytes, which are responsible for maintaining the structure and function of cartilage in joints. The infection of chondrocytes can lead to the dysregulation of various genes associated with joint inflammation and tissue remodeling, potentially contributing to the development of arthralgia.
Similarly, osteoblasts, which are involved in bone formation, and synoviocytes, the cells lining the synovial membrane of joints, have also been shown to be permissive to MAYV infection. Infection of these cells can result in the upregulation of inflammation-related genes, immune response, and extracellular matrix remodeling, which are implicated in joint pathology.
During MAYV infection, macrophages can become infected and serve as viral reservoirs. Infected macrophages produce pro-inflammatory molecules, such as tumor necrosis factor alpha. TNF-α promotes the recruitment of immune cells and amplifies the inflammatory response, contributing to the development of arthritis. Additionally, macrophages generate excessive reactive oxygen species, leading to oxidative stress and tissue damage, including joint damage.
Innate immune response:
Infection of bone marrow-derived macrophages with the Mayaro virus (MAYV) leads to the upregulation (overexpression) of essential inflammasome proteins. In particular, the NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) and AIM2 (absent in melanoma 2) inflammasomes have been implicated in response to MAYV infection. Activation of these inflammasomes triggers the assembly of the inflammasome complex, including the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and subsequently activates caspase enzymes.
The activation of caspases, particularly caspase-1, leads to the synthesis and release of pro-inflammatory cytokines, like interleukin-1β (IL-1β) and interleukin-18 (IL-18), essential mediators of the inflammatory response. The upregulation of NLRP3, AIM2, ASC, and caspase proteins in infected macrophages indicates the involvement of the inflammasome pathway in the host immune response to MAYV infection.
Antibody response:
MAYV stimulates the production of immunoglobulin M (IgM) antibodies during acute infection. IgM antibodies are the first to produce in response to an infection and indicate a recent or active immune response. MAYV-specific IgM antibodies typically last for at least three months after the onset of clinical symptoms, serving as an indicator of recent infection.
On the other hand, the presence of immunoglobulin G (IgG) antibodies indicates prior exposure or infection with MAYV. IgG antibodies are produced later during the immune response and persist for longer, even after the infection has resolved.
Mayaro virus (MAYV) infection in humans can lead to various clinical manifestations like other arboviral diseases.
Fever:Mayaro virus infection typically presents with a sudden onset of high fever, often exceeding 39°C (104°F).
Joint and muscle pain: Severe joint pain (arthralgia) is a hallmark of the Mayaro virus infection. It commonly affects the large joints such as the knees, ankles, and wrists. Muscle pain (myalgia) and stiffness are also frequently reported.
Rash: Many individuals infected with the Mayaro virus develop a rash, which can vary in appearance and distribution. The rash is often maculopapular (flat or slightly raised) and may affect the trunk, limbs, and face.
Headache: Headache, including retro-orbital pain (pain behind the eyes), is commonly reported in Mayaro virus infection.
Fatigue: Profound fatigue and weakness are common symptoms during the acute phase of the Mayaro virus infection.
Other symptoms: Additional symptoms that may be observed include nausea, vomiting, diarrhea, sore throat, conjunctivitis (inflammation of the conjunctiva), and respiratory symptoms like coughing.
ELISA: It detects and quantifies specific antibodies (IgM and IgG) produced in response to MAYV infection. The test relies on antigen-antibody binding, where MAYV-specific antigens are immobilized on a solid surface, and the patient’s serum is added. If the patient has been infected with MAYV, the specific antibodies will bind to the antigens. The presence and number of MAYV-specific antibodies can be measured using enzyme-labeled secondary antibodies and a colorimetric substrate.
Complement fixation: Antibody affinity to the E2 protein of the Mayaro virus (MAYV) refers to the strength of binding between antibodies and the E2 protein, a viral envelope protein. Antibodies with higher affinity exhibit stronger binding interactions with the E2 protein. Binding to the E2 protein is essential for the immune response against MAYV, as antibodies that bind to E2 can neutralize the virus by preventing its attachment to host cells and interfering with viral replication. The neutralization of anti-MAYV monoclonal antibodies (mAbs) occurs when these antibodies bind to E2, inhibiting viral infectivity. The complement fixing experiment is an immunological technique to identify antibodies against MAYV. Blending patient serum with MAYV antigens & complement proteins resulted in complement activation & concurrent lysis of indicator cells, demonstrating the existence of specific antibodies against the Mayaro virus.
Neutralization tests: These tests assess the ability of patient serum to neutralize the infectivity of MAYV in cell culture. In a neutralization test, patient serum samples are diluted and mixed with a standardized amount of live MAYV. The serum-virus mixture is then added to susceptible cells and incubated. If the patient’s serum contains specific antibodies against MAYV, these antibodies will bind to the virus, preventing it from infecting the cells. The neutralization effect is measured by assessing the cell level of viral replication or cytopathic effect. A decrease or absence of viral replication indicates the presence of neutralizing antibodies and confirms the diagnosis of MAYV infection. Neutralization tests provide a specific and sensitive means of detecting antibodies against MAYV and are particularly useful in determining past or recent exposure to the virus.
When diagnosing Mayaro virus infection, it is crucial to consider possible cross-reactions; the Alphavirus genus shares similar antigenic properties, leading to potential cross-reactivity in serological tests. Cross-reactivity means that antibodies produced in response to one virus may also recognize and bind to antigens of another virus. Accurate diagnosis of MAYV requires using specific antigens and careful interpretation of serological test results to differentiate between MAYV-specific antibodies and those generated against chikungunya virus or O’nyong-nyongvirus.
RT-PCR test: The design of a reverse transcription real-time PCR (rRT-PCR) targeting a region of the 5′ untranslated region (UTR) and nsp1 gene of Mayaro virus allows for accurate detection of the virus. The 5′ UTR region is conserved in the viral genome, while the nsp1 gene encodes a non-structural protein. The rRT-PCR assay can detect and amplify the Mayaro virus genetic material in clinical samples by targeting these specific regions.
Vector control: Since MAYV is primarily transmitted by mosquitoes, controlling mosquito populations is crucial. It can be achieved by eliminating breeding sites, using insecticide-treated bed nets, applying insect repellents, and implementing community-based mosquito control programs.
Individuals living in or visiting areas where MAYV is endemic should take personal protective measures, including wearing long-sleeved clothing, using insect repellents, and staying in screened or air-conditioned accommodations to minimize mosquito bites.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
